Chemotherapy-Induced Neutropenia Pipeline Insight, 2025: Advancing Therapies Aim to Mitigate Life-Threatening Complications of Cancer Treatment | DelveInsight

Chemotherapy-Induced Neutropenia (CIN) remains one of the most common and serious hematologic complications in oncology, significantly increasing the risk of infection, treatment delays, dose reductions, and associated healthcare costs. CIN results from the cytotoxic effects of chemotherapy on bone marrow, leading to a dangerously low neutrophil count, often requiring proactive management strategies to maintain treatment intensity and improve patient outcomes.

DelveInsight's "Chemotherapy-Induced Neutropenia - Pipeline Insight, 2025" offers a detailed evaluation of the evolving therapeutic pipeline, featuring diverse clinical and preclinical candidates. These include long-acting G-CSF formulations, novel cytokine mimetics, biosimilars, and investigational agents that target neutrophil production and mobilization through distinct mechanisms.

Key players in the CIN therapeutic landscape include Aileron, Enzychem Lifesciences, Myelo Therapeutics GmbH, and BeyondSpring, among others. Several of these companies are developing therapies aimed at addressing unmet needs such as reduced administration frequency, lower immunogenicity, and enhanced neutrophil recovery in high-risk populations.

The report also highlights ongoing clinical trials with next-generation agents like Plinabulin, a first-in-class selective immunomodulating microtubule-binding agent (SIMBA), and efbemalenograstim alfa, a novel long-acting G-CSF analog. These therapies are showing potential in reducing the incidence and duration of CIN while maintaining or enhancing chemotherapy dose intensity.

With an increasing focus on patient-centric care, risk stratification, and cost-effective management, the CIN pipeline is poised to redefine supportive oncology care, offering innovative solutions that could prevent severe complications and improve quality of life for cancer patients undergoing chemotherapy.

Interested in learning more about the current treatment landscape and the key drivers shaping the Chemotherapy-Induced Neutropenia pipeline? Click here: https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Chemotherapy-Induced Neutropenia Pipeline Report
• DelveInsight's Chemotherapy Induced Neutropenia pipeline analysis depicts a strong space with 3+ active players working to develop 3+ pipeline drugs for Chemotherapy Induced Neutropenia treatment.
• The leading Chemotherapy Induced Neutropenia companies include Aileron, Enzychem Lifesciences, Myelo Therapeutics GmbH, BeyondSpring Inc., and others are evaluating their lead assets to improve the Chemotherapy Induced Neutropenia treatment landscape.
• Key Chemotherapy Induced Neutropenia pipeline therapies in various stages of development include ALRN-6924, EC-18, myelo001, Plinabulin, and others.
• In June 2025, Mavorixafor received FDA Fast Track designation for chronic neutropenia (different from CIN) in a Phase III trial (4WARD), marking an acceleration in development
• In February 2025, ImmunityBio announced that the FDA granted RMAT designation to ANKTIVA® and CAR-NK (PD-L1 t-haNK) for reversing lymphopenia in patients undergoing standard chemotherapy/radiotherapy and those with advanced pancreatic cancer.

Request a sample and discover the recent breakthroughs happening in the Chemotherapy Induced Neutropenia pipeline landscape at https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Chemotherapy-Induced Neutropenia Overview
Chemotherapy-induced neutropenia (CIN) is a frequent and serious complication observed in cancer patients undergoing cytotoxic chemotherapy. It often emerges as a dose-limiting toxicity, prompting treatment delays, dose reductions, or the need for additional supportive care, ultimately affecting the efficacy of cancer therapy. CIN can also escalate into chemotherapy-induced febrile neutropenia (CIFN), a medical emergency that increases healthcare costs due to hospitalization, diagnostic procedures, and antimicrobial treatment.

Beyond neutrophil depletion, CIN is frequently accompanied by reductions in other blood cell types, such as red blood cells (anemia) and platelets (thrombocytopenia), further complicating patient management. Chemotherapy dosing is carefully tailored to minimize the severity of these adverse events, and in cases of severe neutropenia, treatment may be paused until blood counts recover, often with the help of growth factor support.

Interestingly, while CIFN is clearly associated with poorer clinical outcomes, the occurrence of CIN alone does not necessarily indicate treatment failure. In some cases, the presence of CIN has been observed as a potential surrogate marker for therapeutic response or improved survival in patients receiving cytotoxic regimens, underscoring the complex role of neutropenia in cancer therapy.

Find out more about Chemotherapy Induced Neutropenia medication at https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Chemotherapy-Induced Neutropenia Treatment Analysis: Drug Profile
ALRN-6924: Aileron Therapeutics
ALRN-6924 is a first-in-class therapy aimed at selectively protecting healthy cells in patients with p53-mutated cancers, helping to prevent chemotherapy-induced side effects without compromising the treatment's ability to target cancer cells.

EC-18: Enzychem Lifesciences
EC-18, Enzychem's lead compound originally derived from Sika deer antler, has been fully synthesized after extensive research. It is being developed for multiple indications, including chemoradiation-induced oral mucositis (CRIOM), chemotherapy-induced neutropenia (CIN), acute radiation syndrome (ARS), COVID-19-related ARDS, immune checkpoint inhibitor-related toxicities, and NASH.

Learn more about the novel and emerging Chemotherapy-Induced Neutropenia pipeline therapies at https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Chemotherapy-Induced Neutropenia Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

By Molecule Type
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Scope of the Chemotherapy-Induced Neutropenia Pipeline Report
• Coverage: Global
• Key Chemotherapy Induced Neutropenia Companies: Aileron, Enzychem Lifesciences, Myelo Therapeutics GmbH, BeyondSpring Inc., and others.
• Key Chemotherapy Induced Neutropenia Pipeline Therapies: ALRN-6924, EC-18, myelo001, Plinabulin, and others.

Dive deep into rich insights for drugs used for Chemotherapy Induced Neutropenia treatment, visit: https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Chemotherapy-Induced Neutropenia Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Chemotherapy-Induced Neutropenia Pipeline Therapeutics
6. Chemotherapy-Induced Neutropenia Pipeline: Late-Stage Products (Phase III)
7. Chemotherapy-Induced Neutropenia Pipeline: Mid-Stage Products (Phase II)
8. Chemotherapy-Induced Neutropenia Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.